In this study, we demonstrated that WBRT plus SIB had promising effect on intra-cranial tumor control and could improve patient survival in breast cancer with brain metastasis, especially in patients with HER2-postive tumors. This treatment approach could be recommended for patients with multiple brain metastases when SRS is not eligible. Brain metastases are common in late-stage lung cancers, breast cancers and malignant melanoma (Lorger & Felding-Habermann, 2010).